Back to news

BioSyent Releases Financial Results for Q3 and YTD 2026

Globe Newswire•17/11/2026•17:45 ET
0

Key Highlights

  • ➤Q3 sales $20.1M, up 64% year over year
  • ➤Q3 EBITDA $5.6M, up 53% year over year
  • ➤YTD net income $8.1M, up 15% year over year
  • ➤Oral Health contributed $7.8M sales and $1.6M EBITDA in Q3
  • ➤Remaining $2M acquisition debt repaid October 1, 2026

Expert Statements

René Goehrum, President and CEO of BioSyent

“Our recently acquired Oral Health business continued to perform well in Q3 2026, its second full quarter of operations as part of BioSyent”

René Goehrum, President and CEO of BioSyent

“When combined with our existing pharmaceutical brands, the Oral Science product catalogue gives us a broad platform for continued future growth, both in Canada and internationally.”

René Goehrum, President and CEO of BioSyent

“With combined operating cash flows of $6.0 million in Q3 2026, we were able to deploy $1.7 million in share buybacks under our ongoing Normal Course Issuer Bid and $0.6 million in dividends during the quarter while continuing to invest in our brands, including Thyconvi(®), as we prepare to launch this product in Canada in the first quarter of 2027.”

René Goehrum, President and CEO of BioSyent

“Additionally, we have fully repaid our remaining acquisition debt of $2.0 million, leaving us with a clean balance sheet and strong cash position to take advantage of future opportunities and to hedge against future risks.”

René Goehrum, President and CEO of BioSyent

“I look forward to reporting on our continuing progress in 2027.”

MISSISSAUGA, Ontario, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q3), nine months (YTD), and trailing twelve months (TTM) ended September 30, 2026. Key highlights include:

(CAD)Q3 2026% Change vs. Q3 2025YTD 2026% Change vs. YTD 2025TTM Sep 30, 2026% Change vs. TTM Sep 30, 2025 Pharmaceutical Sales11,530,182+5 %33,443,654+6 %42,837,694+7 % Oral Health Sales7,814,229n/a19,023,604n/a19,023,604n/a Insecticide Sales740,176-39 %1,398,274-26 %1,676,157-15 % Total Company Sales20,084,587+64 %53,865,532+61 %63,537,455+51 % EBITDA (1)5,572,805+53 %14,188,144+48 %16,716,705+41 % Net Income After Taxes (NIAT)2,860,465+7 %8,054,721+15 %10,046,509+16 % Fully Diluted EPS0.25+8 %0.70+15 %0.87+16 %

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in